Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03425097 · ClinicalTrials.gov registry record · Phase 2
Fexofenadine Use in Gastroesophageal Reflux Symptoms
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03425097: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT03425097 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03425097, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The investigators wish to study the effectiveness of Fexofenadine (an over the counter allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still have symptoms despite being on a proton pump inhibitor. The investigators will do this by giving participants both Fexofenadine (an H1 blocker) for 2 weeks and placebo (sugar pill) for 2 weeks. The participants will not know which drug they are getting at a particular time. This will help the investigators better assess the true effectiveness of Fexofenadine.
Interventions
- DRUG Fexofenadine
- DRUG Placebo - Cap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2019-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03425097
The ClinicalTrials.gov registry entry for NCT03425097 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fexofenadine is the first listed.
NCT03425097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03425097 about?
NCT03425097 is a clinical study titled "Fexofenadine Use in Gastroesophageal Reflux Symptoms". The investigators wish to study the effectiveness of Fexofenadine (an over the counter allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still have symptoms despite being on a proton pump inhibitor. The investigators will do this by giving participants both Fexofena...
What is the current status of trial NCT03425097?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-02-07. Estimated completion is 2019-01-08.
What interventions are being tested in trial NCT03425097?
The interventions under investigation include: Fexofenadine (DRUG), Placebo - Cap (DRUG).
Who is sponsoring clinical trial NCT03425097?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.